Latest From TherOx Inc.
Just months after receiving USA FDA approval for its SuperSaturated Oxygen (SSO2) Therapy for heart-attack treatment, Californian company TherOx has been acquired by Zoll Medical for an undisclosed sum.
A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker. This week, FDA approved TherOx’s Supersaturated Oxygen System. PharmaEngine/Nanobiotix said its Hensify NBTXR3 nano-particles received the CE mark and plans to market it in 27 European countries for treating locally advanced soft tissue sarcoma.
Clinical trials have shown that SuperSaturated Oxygen Therapy (SSO2 Therapy) reduces the size of myocardial infarcts in the regions of the heart-muscle perfused by the patient’s left anterior descending coronary artery immediately following stenting.
The US Medicare agency granted inpatient new-technology add-on payments for Boston Scientific's newly acquired cerebral protection system for TAVR, Respicardia's neurostimulator for sleep apnea and Procept BioRobotics' novel resection system for benign prostatic hyperplasia. The highly selective bonus payments typically help drive adoption for the chosen new technologies.
- Medical Devices
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- TherOx Inc.
- Senior Management
Kevin T Larkin, Pres. & CEO
Shelley Thunen, CFO
Robert K Weigle, VP, Sales & Mktg.
- Contact Info
Phone: (949) 757-1999
17500 Cartwright Rd.
Irvine, CA 92614-5846
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.